# Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

> **NCT00290810** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 12 (actual)

## Conditions studied

- B-cell Chronic Lymphocytic Leukemia
- Refractory Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** bevacizumab

## Key facts

- **NCT ID:** NCT00290810
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-12
- **Primary completion:** 2008-10
- **Final completion:** 2010-08
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2014-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00290810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00290810, "Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00290810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*